Indacaterol on dyspnea in chronic obstructive pulmonary disease: A systematic review and meta-analysis of randomized placebo-controlled trials

Indacaterol is a novel, once-daily (od), inhaled, long-acting ß2-agonist bronchodilator for maintenance treatment of airflow limitation in patients with COPD. The aim of this study was to evaluate the efficacy of indacaterol on dyspnea, using available randomized placebo-controlled trials.